Tricyclic antidepressants (TCAs) work primarily by blocking the reabsorption of two chemical messengers in the brain: serotonin and norepinephrine. By preventing these neurotransmitters from being pulled back into the nerve cell that released them, TCAs keep higher concentrations available in the gap between neurons, strengthening the signals those chemicals carry. But this core mechanism is only part of the story. TCAs interact with at least five different neurotransmitter systems, which explains both their broad usefulness and their notable side effects.
The Core Mechanism: Blocking Reuptake
After a nerve cell fires and releases serotonin or norepinephrine into the synapse (the tiny gap between two neurons), the sending cell normally vacuums those molecules back up through specialized transporter proteins. This recycling process, called reuptake, clears the signal quickly. TCAs physically block those transporter proteins, so serotonin and norepinephrine linger in the synapse longer and stimulate the receiving neuron more effectively.
Not all TCAs block both chemicals equally. The older, “parent” compounds (called tertiary amines) tend to block serotonin reuptake more strongly. When your liver metabolizes these into smaller molecules (called secondary amines), the balance shifts toward blocking norepinephrine reuptake instead. This distinction matters clinically. Dual-action TCAs that strongly block both serotonin and norepinephrine, like amitriptyline and clomipramine, have shown a slight efficacy edge over SSRIs in hospitalized patients with severe depression. A meta-analysis found amitriptyline specifically outperformed SSRIs in that population, possibly because of this dual action.
Why TCAs Cause So Many Side Effects
Unlike newer antidepressants that target serotonin or norepinephrine fairly selectively, TCAs also bind to several other receptor types throughout the body. These “off-target” effects are responsible for most of the side effects people experience.
- Histamine receptors: Blocking histamine signaling causes drowsiness, weight gain, and sedation. This is the same mechanism behind antihistamine allergy medications that make you sleepy.
- Muscarinic receptors: Blocking acetylcholine at these receptors leads to dry mouth, blurred vision, constipation, urinary retention, and sometimes confusion, especially in older adults.
- Alpha-adrenergic receptors: TCAs block a type of norepinephrine receptor on blood vessels, which can cause dizziness when standing up (orthostatic hypotension). Research has shown that TCAs also act as unusual signaling molecules at these receptors, triggering a process that gradually reduces the number of receptors on the cell surface with chronic use.
These additional receptor interactions are not therapeutic for depression. They are essentially collateral effects of a molecule that is not precise enough to hit only its intended targets. This “dirty” pharmacology is the main reason SSRIs largely replaced TCAs as first-line antidepressants, despite TCAs being at least equally effective for depression itself.
How TCAs Relieve Chronic Pain
TCAs are widely prescribed off-label for chronic pain conditions like diabetic neuropathy, postherpetic neuralgia, and myofascial pain. The pain-relieving mechanism is distinct from the antidepressant effect, and there are two clear pieces of evidence for this. First, TCAs reduce pain even in people who are not depressed. Second, pain relief kicks in within days to a week, while the antidepressant effect typically takes two to four weeks.
The pain relief works mainly through norepinephrine. When TCAs increase norepinephrine levels in the spinal cord, that norepinephrine activates receptors on pain-transmitting nerve cells in the dorsal horn (the part of the spinal cord that processes incoming pain signals). These receptors shut down pain transmission in two ways: they reduce the release of excitatory chemicals from incoming pain fibers, and they make the receiving spinal cord neurons less excitable by changing the electrical charge across their membranes.
There is also a second, broader effect. The increased norepinephrine activates a brain region that sends inhibitory signals back down the spinal cord, essentially turning up the volume on the body’s built-in pain suppression system. In people with chronic pain, this descending inhibitory pathway is often impaired, and TCAs help restore it.
How Your Body Processes TCAs
TCAs are broken down primarily by a liver enzyme called CYP2D6, and this is where genetics create significant variation between people. About 7% of people of European descent lack a functional version of this enzyme entirely. These “poor metabolizers” clear TCAs from their blood much more slowly, meaning standard doses can build to levels that cause serious side effects. At the other extreme, some people carry extra copies of the CYP2D6 gene and break TCAs down so fast that normal doses may never reach effective levels.
The frequency of these genetic variations differs across populations. Ultrarapid metabolizers (people with duplicated genes) make up 1 to 2% of the population in Sweden but as many as 29% in Ethiopia and 20% in Saudi Arabia. Meanwhile, a reduced-activity gene variant is found in about 50% of Chinese, Japanese, and Korean populations but is rare in Europeans. These differences mean the same dose of a TCA can produce wildly different blood levels in different people, which is why doctors sometimes order blood tests to check drug levels. For example, the target combined blood level for amitriptyline and its active breakdown product is 80 to 200 nanograms per milliliter, measured just before the next dose.
Cardiac Effects and Overdose Risk
The most dangerous property of TCAs is their ability to block sodium channels in the heart. These channels control the electrical impulse that coordinates each heartbeat. When TCAs block them, the electrical signal takes longer to travel through the heart muscle, widening a specific part of the heart’s electrical tracing called the QRS complex. In therapeutic doses, this effect is usually minor. In overdose, it can become life-threatening, causing abnormal heart rhythms, conduction blocks, and cardiac arrest.
On an ECG, TCA toxicity can show up as prolonged PR, QRS, and QT intervals, along with unusual patterns that mimic other cardiac conditions. These changes typically peak within 12 hours of an overdose but can take up to a week to fully resolve. A QRS duration wider than 100 milliseconds is one marker doctors use to assess the severity of TCA poisoning, though it is not a perfect predictor of complications. This narrow margin between therapeutic and toxic doses is a major reason TCAs are prescribed cautiously, and why they are rarely chosen as a first-line antidepressant when safer alternatives exist.
What TCAs Are Used For Today
TCAs are FDA-approved for major depressive disorder, with clomipramine also carrying an approval for obsessive-compulsive disorder in people aged 10 and older. Seven TCAs remain on the market in the United States: amitriptyline, amoxapine, desipramine, doxepin, nortriptyline, protriptyline, and trimipramine.
In practice, TCAs are now prescribed more often for their off-label uses than for depression. These include migraine prevention, insomnia (particularly low-dose doxepin), anxiety disorders, and a range of chronic pain conditions. For neuropathic pain especially, TCAs remain a mainstay of treatment because their dual action on serotonin and norepinephrine in the spinal cord makes them more effective pain relievers than antidepressants that target only one of those chemicals.